Bias in Research: The Word is Spreading

Dr. John Grohol over at PsychCentral has issued an excellent post on bias in research. He aptly describes some of the many biases that enter into the research process and why we'd better be quite careful before we jump on the evidence based medicine bandwagon. A teaser follows, in which he discusses evidence based medicine:

It’s like buying a 14-chapter book expecting to get the entire story. But instead of getting the entire story, you find chapters 10-14 are missing, and that chapters 3-9 were written by an author that didn’t appear on the front cover of the book. But it’s not quite so obvious as that. Nobody tells you that chapters 3-9 were written by someone else, and nobody mentions that it’s actually a 14-chapter book that’s missing 5 chapters. It’s no wonder you come away from the book feeling a little confused and betrayed. It’s nothing like you expected or were promised.

Very well said! I salute his excellent post and refer all readers to check it out. For a somewhat similar and certainly windier take on bias in the research process, please read my earlier post.

Hat Tip: Furious Seasons

The Mask, Missing Safety Studies, WHO, and More

A few links to posts I've found notable and relevant the past few days, then likely not much more out of me for the day...

Pharma Giles insists on continually being funny. Just a heads up that the latest post there is laugh-inducing. It involves a Darth Vader mask, a Hannibal Lechter mask, satire regarding Exubera, and more.

Oh, and the rant on the Pharma Giles site from last week was a thing of beauty.

As if Exubera is not getting kicked around enough, Brandweek attempts to slam more nails into the coffin of the bong-like insulin inhaler. A great read.

Meanwhile, Furious Seasons was among the first to discuss some of Marcia Angell's prescient comments regarding the drug industry. Did you know, for example, that drug companies frequently promise the FDA that they will conduct studies regarding the safety of their products, yet about 70% of these studies have apparently never been conducted?? Are you kidding me?

PharmaGossip notes that Abbott is cutting scientists from its workforce. Hopefully the marketing staff is safe. Insider also notes that the counter-detailing movement has started. Yep, individuals are hitting doctors' offices armed with science rather than sales scripts, sometimes even suggesting (*gasp*) that physicians may want to prescribe older, less expensive treatments! Oh the horror! Could this movement catch on?

Last, but not least, Health Care Renewal has posted on the World Health Organization seemingly accepting money from drug companies after the money was first laundered by patient advocacy groups.

Prepare to NOT be Shocked: Clinical Trials are Biased

Dr. Jeffrey Peppercorn and colleagues recently conducted an analysis of cancer drug trials to examine whether industry funding was associated with a greater likelihood of finding positive results. What did they find?

In 2003, the likelihood of positive results was 84 percent for studies with pharmaceutical involvement, versus 54 percent in studies without clear industry connections. Our analysis was small, consisting only of 140 trials, but similar associations have been documented before, in stroke trials, psychiatry trials, cardiovascular trials and several other areas of clinical research.

An earlier post has detailed how the whole publication process is biased and this latest story appears to be just another cog in the machine.

Hat Tip: eDrugSearch Blog.

Cymbalta for GAD: Repeating the Pattern

Lilly's drug Cymbalta (duloxetine, aka Yentreve) was approved by the FDA as a treatment for generalized anxiety disorder today.

Is this good for people with GAD? Is this good for Lilly? Are there any academic cheerleaders in the house?

People with GAD: Sometimes a medication really does a good job in treating symptoms and sometimes there are red flags that the science does not match the marketing. In this case, it took very little digging to find a red flag – just read the press release!

In clinical trials, on average, patients treated with Cymbalta for generalized anxiety disorder experienced a 46 percent improvement in anxiety symptoms compared to 32 percent for those who took placebo, as measured by the Hamilton Anxiety Scale [HAM-A].

I have not seen the full text of what appears to be the only published study of Cymbalta for GAD. I cannot find the other two duloxetine studies on Medline (the press release claims there have been three studies), which seems odd. Perhaps I should dig a little deeper… In any case, let’s move on to the efficacy of duloxetine in the study referenced in the press release.

My guess (from a similar study examining Zoloft for GAD) is that participants averaged about 25 on the HAM-A at the start of treatment. Using the press release’s numbers, the Cymbalta group comes down to an average of 13.5 while the placebo group came down to an average of 17. Is a difference of 3.5 points on the HAM-A noticeable? Could a clinician tell the difference between someone with a 17 and a 13.5 on this measure? I think that in most cases, yes. But it is probably a small difference.

Adverse events reporting in press releases (and often in journal reports) is a joke, so I am not sure about the safety of the compound. The infamous Traci Johnson case suggests that there may be a risk of suicidality with Cymbalta, but I would prefer to see more data before making a firm association. Of course, given the general link between SSRIs (and newer antidepressants) and increased suicidality, my initial instinct is to be leery of Cymbalta in this regard.

Good for Lilly: This is great news for Lilly. As the Zyprexa debacle continues to unfold, Lilly’s search for good news appears to have arrived in Cymbalta. According to the Indianapolis Star, Cymbalta sales hit $1.3 billion in 2006. With the GAD indication and its rapid expansion into the depression market, I’m guessing that we’re looking at least a $2 billion drug for 2007. Not bad for a drug that has no evidence of working better than any of the older, now mostly off-patent SSRIs.

Academics in the House: Dr. Susan Kornstein of Virginia Commonwealth University, whom I have mentioned in the past in relation to her highly positive statements about Lexapro, is back. In the press release, she states:

With this approval, physicians and patients will be happy to know that there is another medication now available to treat this debilitating condition.

Yeah, they’ll be dancing in the streets. With all SSRIs likely showing similar efficacy to Cymbalta and with psychotherapy showing pretty good (but not great) outcomes for GAD (likely better in the long-term than with meds), we needed a more expensive medication because… WHY?

It is amazing how the pattern repeats itself. Show a medication is at least a bit better than a placebo in the short-term, have an “independent” academic give it the stamp of approval, then talk about how it is an important new addition that will prevent untold amounts of grief and suffering. The safety data are often glossed over and the benefits compared to existing treatments are not discussed at all. This helps people (outside of the sponsoring company)… HOW?

Seroquel for Everything Update: Depression

Nothing like an antipsychotic for depression, eh? Well, apparently AstraZeneca is hoping that is the case. They are currently investigating Seroquel (quetiapine) as a treatment for depression.

On their clinical trials website, I noted eight studies currently (or in the near future) examining Seroquel for depression. Not bipolar disorder -- depression. One of these studies is recruiting exclusively elderly patients. This is just the latest in the Seroquel for everything campaign, which includes generalized anxiety disorder, alcohol abuse, public speaking anxiety, anorexia, and likely more. Can you say "Zyprexa: The Sequel"?

Are we really all that surprised that AstraZeneca is being sued for off-label marketing of Seroquel?

Pressured to Prescribe

In this interesting account in the LA Times, a physician, Dr. Marc Siegel, discusses how he was pressured by a Lilly sales representative to prescribe Zyprexa (olanzapine). All emphases are mine.

Looking at my supply closet, I was suddenly struck by the boxes of Zyprexa samples piled high inside. I'm an internist, a doctor who treats sore throats and high blood pressure. This medication was an antipsychotic drug designed to treat the severe delusions and agitation of bipolar disorder and schizophrenia.

What are these doing here? I asked my office nurse. The drug rep brought them, she said. She wants to speak to you.

What did the rep say?

She said that I was likely seeing bipolar patients, as well as demented patients who were agitated.

Moving ahead a bit...

At that point, she said the company had given her a directive to reach out to as many internists as possible. The company felt that we internists as a group were underutilizing the drug, she said.

That's dangerous thinking, I replied. I told her that such persistence would no doubt lead to the drug being wrongly prescribed — that it would hurt patients.

Dr. Siegel also stated that

Although psychiatrists are not always available and not all patients are willing to see them, doctors must carve out our areas of expertise in keeping with our training and experience, and depression and psychosis are simply not my areas as an internist.

You mean that non-mental health specialists should not be doling out Zyprexa, Risperdal, Seroquel, and the like willy-nilly? Sounds good to me -- of course, psychiatrists should also be careful of what they prescribe and take a close look at the evidence behind the medicines they hand out to patients. On another note, Siegel's story ties in nicely with other evidence regarding the apparent off-label promotion of Zyprexa.

Whisteblower Gets Smacked: What a Story...

Health Care Renewal has a post that tells a striking story about what can happen to whistleblowers. Here's the abbreviated version...

Paul Kornak (who went by Dr. Kornak yet never completed medical training) fiddled with medical records in drug studies and, adding injury to insult, apparently pled guilty to negligent homicide of a patient in a chemotherapy study. Making this tragic tale even worse was that when a few brave souls attempted to blow the whistle on dear Mr. Kornak, they were punished. This scandal could not be put at the feet of a greedy corporation... this was all done in the VA medical system. The retribution taken against the whistleblowers involved the loss of employment and trumped-up charges of patient abuse and practicing medicine outside of competence areas. If you think the teaser sounds bad, wait until you read the whole story.

Read more about the story at Health Care Renewal.

Zyprexa Does Not Cause Diabetes?

That's not what one set of physicians believe, despite Lilly's protestations to the contrary. Here's what they recently reported regarding one case:

The authors report a case with life-threatening hyperglycemia and acidosis in a patient with no previous diabetic history following treatment with olanzapine. A 35-year-old woman with a history of bipolar affective disorder treated with olanzapine presented with severe diabetic ketoacidosis. She had no prior history of diabetes or risk factors for diabetes. Glycosylated hemoglobin (HbA1c) on admission blood sample suggested that long-term glycemic control had been poor. The authors postulate that treatment with olanzapine precipitated hyperglycemia, an elevated creatine kinase level, and a high amylase level.

Perhaps someone should have told these physicians that Zyprexa is a safe, gentle psychotropic that could not possibly induce such nasty side effects.

Return of the Sponsored Editorial

It's baaaaack! A reader informed me that the AstraZeneca-supported "sponsored editorial" which appeared earlier in the Journal of Clinical Psychiatry has now reared its ugly head in the January issue of Current Psychiatry.

As I've pointed out earlier, a sponsored editorial should never be allowed in a journal. If a journal is supposedly independent of its advertisers, how can an editorial (which reflects the opinion of the journal's editorial board) be sponsored? This same Seroquel advertorial has also appeared in the Journal of Clinical Psychiatry and, I suspect, in other psychiatry journals.

Irrelevant Bagel Rant

I think that complaining about the Blogger switch cued me to other complaints. Like this one...

I was at Bruegger's Bagels the other day. I was asked if I'd like my bagel sliced. I responded in the affirmative. Looking at my receipt, I noted that it cost 25 cents to have it sliced. It took about five seconds to slice.

That is $3 per minute and $180 per hour. To slice a damn bagel.

Mind you, I was not told it would cost me a red cent -- she put it to me as if it were a favor. With adorable little doe eyes, she asked, "Would you like your bagel sliced?" What was I going to do, say no?

Some Problems Fixed

This allegedly easy upgrade to New Blogger is still a bit troublesome. Some of my posts look odd in Internet Explorer. I need to fool with my template. In the meantime, I've figured out (with a lot of help) the evil line of code that caused me to get dropped from Google, so that should be fixed.

Update: Martha post fixed. I also accidentally beheaded my blog (took the head out of the template) and then reattached it. The operation appears to have been successful, but we'll see.

For anyone else who has the joy of switching from old Blogger to new Blogger, make sure that you check out this link.

Thanks to several readers for their helpful input on (hopefully) resolving this problem.

Blogger Annoyances

Ever since I switched to the "new and improved" Blogger, my hits have been way down. This seems to be largely because this site no longer appears in results for Google searches nor in Google blog searches that used to garner me plenty of hits.

I even more greatly appreciate the links from various blogs lately, as they have been the only source of traffic for me outside of my regular readers.

Equally as annoying are the blogs that steal my content word for word and then repost it on their sites as if they wrote it. That is called plagiarism and I don't like it. Sarahparkin.com is a great example -- that site shows all of my posts as well as posts ripped from other blogs word for word without any credit being given to the authors. Even worse, sarahparkin.com now shows up in Google searches and my site does not. Figure that out.

Furious Seasons Nails It

Furious Seasons has a lengthy and excellent post where several issues regarding Zyprexa are discussed, including its marketing for bipolar disorder, as well as how side effects were to be downplayed. Check it out here. It's great work.

Demented Marketing of Zyprexa?

Background: There has been prior mention of how Zyprexa was allegedly marketed off-label as a treatment for dementia, including writing by Alex Berenson. This post will provide more details regarding this issue, especially about the hypothetical case of “Martha,” a case used by Lilly sales representatives in their meetings with physicians.

Before reading this piece, please note that Lilly has denied that it markets its products off label.

Martha’s symptoms have been described as much more strongly resembling dementia than either schizophrenia or bipolar, the only two indications for which Zyprexa is FDA approved. According to Alex Berenson, Martha was described as

a widow with adult children "who lives independently and has been your patient for some time." Martha was described as being agitated and having disturbed sleep, but without the symptoms of paranoia or mania that typically marked a person with schizophrenia or bipolar disorder.

Berenson noted that a Lilly spokesperson said that Martha was intended to represent a patient with schizophrenia.

More on Martha: Here is more on Martha, perhaps from the same document examined by Berenson. This document is titled Zyprexa® (olanzapine) Primary Care Q3 Implementation Guide, and it is dated June 2001.

This is Martha. Martha is a widow who lives independently and has been your patient for some time. She is becoming more complicated to manage, and you note increasing agitation. Her sleep is disturbed; she dozes during the day and is up most of the night. Her family has shared their concerns with you, saying, “She thinks we’re trying to take advantage of her.”

Martha’s family doesn’t want to send her to a nursing home, but her agitation and confusion must be addressed. Your goals of treatment for Martha may include reducing her behavioral disturbances without impairing her cognitive functioning.

Does Martha Have Schizophrenia? Upon checking the Diagnostic and Statistical Manual for Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia, it appears that Martha does not meet the diagnostic criteria for schizophrenia, despite Lilly’s claims that Martha was intended to represent a patient with schizophrenia.

Later, the same document discusses possible Zyprexa dosage for Martha.

…a starting dose of 5mg – or even 2.5 mg – at bedtime is appropriate.

In schizophrenia trials, Zyprexa is typically dosed at 10-20 mg, not 2.5 mg-5 mg. This also apparently contradicts Lilly’s claim that it was intending Martha to represent a patient with schizophrenia, as it would make little sense for Lilly to recommend a subtherapeutic dose of Zyprexa to physicians.

Under the heading of Back Cover/Close, it is stated:

In summary, doctor, prescribing ZYPREXA is a safe, proven solution for patients like Martha/Michael/Kelly who suffer with mood, thought, and behavioral disturbances. It’s easy to use, and it works [emphasis in original].

Again, note the broad terminology. Rather than discussing bipolar disorder or schizophrenia, for which Zyprexa is indicated, the language of “mood, thought, and behavioral disturbances” is in place, which suggests much a broader application of Zyprexa.

In the same document, a potential question that reps may receive from doctors is mentioned:

With Martha I would just prescribe a cholinesterase inhibitor, such as Aricept. They are supposed to be pretty good with agitation.

Rep: …Why not prescribe ZYPREXA, which has proven efficacy for agitation and related behavioral disturbances [my emphasis], has been on the market for more than 4 years, and has helped over 6 million patients with symptoms just like Martha’s?

In the case of Martha, note again that schizophrenia is not mentioned; instead, “agitation and related behavioral disturbances” are brought to the fore.

FDA Indication for Dementia? In the same document, under the heading of “Helpful Hints,” subheading titled “Martha Spread,” it is stated that

…You will note that on the right-hand side of the spread under the cognition information is a space that has been intentionally left open. Upon launch of the IM [intramuscular] formulation of ZYPREXA, we will be placing a sticker in this spot to announce the new formulation and new indication (agitation associated with dementia) [my emphasis].

Zyprexa was never approved by the FDA for the treatment of dementia, though it would appear from the above quote that Lilly was expecting such approval.

Email Message: To shed further light on the possible off-label promotion of Zyprexa for dementia, further documents were reviewed, including an email issued to “Area Zyprexa Champions,”

Since the diagnosis of our 3 patients in the Zyprexa core message piece are: Martha – dementia,[my emphasis]…can you enlighten us a little more about dementia. We know that we are to describe the symptoms and stay away from diagnoses, but for our own background, can you elaborate on dementia…We are getting a little grief from some of our docs about promoting Zyprexa for dementia [my emphasis], but according to the slides in the audioconference set, there is no FDA approved drug for dementia.

This email clearly indicates that at least some individuals at Lilly were seeing Martha as a case of dementia and that some doctors seemed upset about Zyprexa being promoted for dementia.

Martha’s Symptoms Increase as She Ages: Another document, titled Zyprexa Retail Implementation Guide states under the heading Sales Call, subheading Patient Profile

Martha is a widow you’ve known and treated for several years. As she’s aged, she’s become more complicated to manage – clinically, and at home. These are comments you hear from her family (read testimonials from profile). Your main goal of treatment is to treat her illness and reduce her behavioral disturbances. Do you see patients like Martha?

The comment of her “becoming more complicated to manage” as she’s grown older sounds much more reminiscent of dementia than of schizophrenia, as with schizophrenia, symptom severity is often rather clear at a relatively young age (twenties and thirties) and does not necessarily worsen over time.

Summary: All told, the documents I reviewed appear to paint a picture of Martha being described as a patient with dementia. Her case was then apparently to be described to physicians in primary care settings in an attempt to open their minds to prescribing Zyprexa. Martha’s symptoms do not seem related to schizophrenia; rather, they seem to more strongly resemble symptoms of dementia. In addition, an email indicated that at least some Lilly employees thought of Martha as a patient with dementia and that some physicians were upset that they perceived Zyprexa was being marketed for dementia.

For more on the story of Zyprexa’s marketing, please see the following (1, 2, 3, 4)

Disclaimer: Please note that I am not equipped to state whether Lilly’s marketing practices regarding Zyprexa were illegal, as the law seems to be pretty unclear on this point.

Of course, whether a practice is legal and whether it is ethical are two different things.

BPS: How to NOT Conduct a Hearing

I’m going to dissect some of the British Psychological Society's fitness to practice hearing for Lisa Blakemore-Brown in which a psychiatrist, Dr. Trevor Friedman, attested to Ms. Brown’s psychological well-being (or lack thereof; background here, here, and here). The testimony occurred on July 12, 2006. Note that Patricia Hitchcock was the counsel for the BPS and Lucy MacKinnon represented Ms. Brown. Kirsty Morrison is the clerk. My comments are interspersed with the hearing’s text.

Ms. Morrison (page 2):… Concerns are that the content and tone of correspondence received by the society from Ms Blakemore-Brown in relation to complaints from Mr and Mrs xxxxxxxxxxx, (inaudible) between May 2003 and May 2005, made repeated references to the attempts from various people, including the complainants, to destroy her career, set her up or discredit her as a professional. This raised concerns that Ms Blakemore-Brown had been suffering from (inaudible) illness, which is affecting her ability to practise.”

Nice start, eh? Brown is allegedly suffering from some form of mental illness because she made references to people trying to destroy her career or discredit her. One can only wonder if David Healy is likewise paranoid; after all, he lost a job (which would generally count as an attempt to destroy one’s career) when he spoke out about the relations between the drug industry and psychiatry, and when he discussed some of the untoward side effects of SSRIs. Let’s move on…

Ms Mackinnon (page 101): “…My application, now that he [Dr. Friedman] is here, is that per se perhaps his evidence is inadmissible on various points given that he has not examined my client.”

Yep, that’s right. Blakemore-Brown has never met with Dr. Friedman, yet Friedman still rendered some significant judgments regarding the mental health of Blakemore-Brown, as we’ll see shortly.

Dr. Friedman (page 107): Yes. Well, I mean, I think I was being careful not to make conclusions or a diagnosis from what is available to me. I think I was just commenting on what seemed reasonable in my opinion having reviewed the documents. In fact, it is a very short report because I did not want to make too many suppositions that one could possibly go to. I just wanted to state what I thought was reasonable.

Ms. Hitchcock (108): Can you explain briefly to assist the committee the nature of paranoia and what its impact could be in the circumstances.

Dr. Friedman (108): Well, I suppose -- I mean the term “paranoia” in itself refers to the idea that people are more sensitive to their surroundings and events that occur to them, so they tend to see extra significance and take inference from otherwise innocuous events. Paranoia generally refers to, I suppose, normally thought of in a kind of persecutory sense in believing that events are occurring around one that in some way are there to harm or malign the person. So that is a sense in which I read these documents, I believe with some maligned conspiracy or motives of other people to, in some way, harm or to damage to Ms Blakemore-Brown.

Ms Hitchcock (108): To what extent does it impact on your views that the facts as seen by Ms Blakemore-Brown may be capable of objective proof? Is it important to your concern that they should not be true?

Dr Friedman (108-109): It does not necessarily have to be not true for people to be suffering from a paranoid illness. It is their interpretation and understanding of events that is important. I mean they sometimes are untrue as well which is obviously of significance as well. But it is generally people’s reasonable interpretation of what has occurred. It is the way they interpret events rather than the events themselves.

Hold the train. Seriously, STOP. So even if people really are out to get you, you are paranoid if you believe that people are out to harm you. Apparently the natural response of fear when one is objectively, realistically threatened, is now paranoia.

The transcript goes on to describe a few specific emails and that Blakemore-Brown’s words were “rather odd,” and that there is a “sheer mass and bulk of documents” which Friedman finds unreasonable, and that the relevance of some of the documents is concerning to Friedman. One of Blakemore-Brown’s letters is then described as “very unusual.” Whether the circumstances faced by Blakemore-Brown were “rather odd” or “very unusual” is apparently not a concern for Dr. Friedman. Again, whether one is actually faced with a frightening situation or not is not a concern.

Dr. Friedman (112): If one sees this as a paranoid illness problem then obviously the person who is affected in this way has to somehow explain what is going on. So the only explanation for that person is to believe that all these things must then be part of the conspiracy because if they are not agreeing with her they must be against her. So as it goes on, the British Psychological Society become apart of this maligned conspiracy or plot to do Ms Blakemore-Brown down. Again that seems unlikely to me.

Wow, how confident! The good doctor knows “the only explanation” for her behavior. I was not aware that behavioral science had reached the level where we could offer “the only explanation” for an individual’s behavior.

Dr. Friedman (113): I mean, the other point about these letters is I find them -- you know, if you are trying to make a case and you are trying to explain what is going on and you think something bad has happened, there is a normal professional way of writing about such matters and many of these emails seem rather disjointed and broken up and, you know, incoherent almost to the point, which is unexpected of an intelligent trained person who is used to writing reports about such matters. So that is another point of concern in terms of worrying about Ms Blakemore-Brown’s state of mind.

Let’s presume for a moment that Ms. Blakemore-Brown is correct that people really were out to get her. If this were the case, then apparently she is expected to maintain a stiff upper lip while acting “appropriately” to channel her complaints. If you become upset in your correspondence, that is apparently another sign of (you guessed it) paranoia.

So did Lisa Blakemore-Brown have reason to be legitimately concerned? I have a feeling that this story will continue to unfold and my suspicion is that, indeed, Ms. Blakemore-Brown had plenty of reason to be concerned, even if not every single one of her concerns was 100% valid.

There is much more in the transcript, which you can download here. I hope to have more time to discuss this further. My understanding is that the transcript is legitimate, though the BPS apparently refuses to comment about it.

Child Bipolar Infuriates Bloggers

Three excellent posts have hit the blogosphere regarding bipolar disorder in children.

Intueri rips the diagnosis apart with pinpoint logical thinking and by pointing out that the “science” behind this disorder is remarkably thin.

Furious Seasons jumps on board as well, adding on to Intueri’s excellent analysis with some of his own characteristically amusing sarcasm. Nice work.

The Last Psychiatrist is also in the house, chiming in with his comments regarding psychiatry’s double standard, why no psych drugs will be getting pediatric indications, and more.

Nice work, bloggers. Keep it coming. If you like their posts, you may also want to check out my latest post on this very topic.

The Ongoing Abuse of the Term Paranoia

In one post, Blumsohn details the claims Blakemore Brown made that were used to label her as “paranoid” by an “expert” witness. More on the “expert” witness to come – suffice to say for now that I hope it does not become standard practice for psychologists to be labeled as “paranoid” by psychiatrists whom they have never met based on the psychiatrists’ interpretation of various documents, most of them emails, regardless of the individual's actual fitness to practice psychology. You can get ahead of the game and read the transcript of the psychiatric testimony at Furious Seasons.

It is interesting that the potential veracity of Blakemore Brown’s claims do not appear to have been examined. If people really are out to get you, then how are you paranoid when you point out that you are in some sort of danger? Mind you, I’m not claiming that paranoia does not exist. I’ve certainly seen paranoia in some people, but just throwing around the term as a political label in order to discredit someone is certainly far from what we should expect from mental health organizations such as the British Psychological Society.

In Blumsohn’s most recent post, he discusses how some researchers seem to have absolutely blown it regarding the prevalence of paranoia. Did you know, for example, that one third of people suffer from “paranoid” fears? Does this seem believable to you? Of course, once someone has been labeled as “paranoid,” then the person can be attacked as “unfit to practice” whatever trade they have learned, as has happened with Lisa Blakemore Brown.

More to come, hopefully soon.

Zyprexa Off Label Marketing (?): Part 2

Disclaimer: I want to make absolutely clear that I am not alleging a crime was committed regarding off-label marketing. I will discuss one of the now famous Zyprexa documents and provide my opinion as to its implications – that’s all I’m doing.

This document is titled: “ZYPREXA – Primary Care Strategy Implementation and Overview” and it was authored by Mike Bandick, brand manager for Zyprexa. All emphases from the document are mine unless noted.

The document states:

Position: Zyprexa: The safe, proven solution in mood, thought, and behavior disorders [emphasis in original]. We will emphasize safety to address barriers to adoption and merchandise the brand’s “Four years – Four million patients” base of experience. The word “solution” speaks to unmet medical need, and enables the PCP to take control of clinical situations that previously had led to referrals and/or poor outcomes. “Mental disorders” is intentionally broad and vague, providing latitude to frame the discussion around symptoms and behaviors rather than specific indications. We will position Zyprexa as the incremental next step in the PCP’s expanding clinical orbit: e.g., SSRI’s => 2^nd generation antidepressants => safe, gentle psychotropics.

Later in the document, it is stated that:

The Zyprexa PCP strategy is designed to fit within the brand vision of broad spectrum efficacy.

There are a number of important points here. Discussion of “intentionally broad and vague” marketing of Zyprexa that provides “latitude” to “frame the discussion around symptoms and behaviors rather than specific indications” points to Lilly apparently marketing Zyprexa off-label. This ties in with another document that pointed toward Zyprexa possibly being marketed for conditions other than schizophrenia or bipolar disorder (see post here).

While PCPs see few patients with schizophrenia or bipolar disorder (especially bipolar I, which is much more impairing than bipolar II), they are certain to see patients who have some “symptoms” or “behaviors” that may overlap with schizophrenia or bipolar. For example, perhaps a male patient is unusually energetic and irritable, yet in no other way resembles an individual with bipolar disorder – does this individual have an “unmet medical need” for Zyprexa? Perhaps this patient is in need of a medication that provides “broad spectrum efficacy” across a wide variety of symptoms and behaviors, as opposed to “specific indications.”

Empowering PCP’s: It is also of note that Lilly appears to be positioning Zyprexa as “the incremental next step in the PCP’s expanding clinical orbit.” First it was PCPs prescribing more and more antidepressants (generally SSRIs) in the 1990’s, and now PCPs are perhaps to be empowered with the ability to prescribe atypical antipsychotics (Zyprexa, in this case) with the same degree of comfort that they now prescribe any other drug? Some of that is, of course, my inference, but it does seem that there was a concerted effort to make PCPs feel more comfortable in prescribing Zyprexa as opposed to making mental health specialty referrals.

The Safe, Proven Solution in Mood, Thought, and Behavior Disorders: To reiterate, this type of slogan really lends itself to off-label marketing. I cannot think of any other reason why Lilly could not have instead used the following: “The safe, proven solution in schizophrenia and bipolar disorder.” As for the issue of "safe," that assertion is also being questioned.

Dislaimer (in case you did not read this first one): Please note that I am not equipped to state whether Lilly’s marketing practices regarding Zyprexa were illegal, as the law seems to be pretty unclear on this point.

Of course, whether a practice is legal and whether it is ethical are two different things.

The document discussed in the post is document number 100589868 and it is available from Furious Seasons here.

Zyprexa: Off-Label Promotion?

The document discussed in this post is called the “Zyprexa Primary Care Presentation”. It appears to be a transcript of a speech Mike Bandick, the Zyprexa Brand Manager, gave at the Eli Lilly National Sales Meeting on March 13, 2001.

It is important to note that Zyprexa is only FDA-approved for use in schizophrenia and bipolar disorder. The document appears to indicate that Bandick was encouraging salespeople to market Zyprexa for treating more than just these two conditions.

Bandick said:

We intend, quite simply, to redefine the way PCPs treat mood, thought and behavioral disturbances. We will continue to focus on symptoms and behaviors that PCPs see every day.

Later he said, referencing Zyprexa:

Broad symptom efficacy in mood, thought, and behavioral disturbances.

It seems curious that Lilly states they did not market Zyprexa for off-label purposes, yet the term “Mood, thought, and behavioral disturbances” seems a fair amount broader than schizophrenia and bipolar disorder. In addition, schizophrenia and bipolar disorder (especially bipolar I, which is the much more severe form of bipolar in comparison to bipolar II) are uncommon disorders. It is highly unlikely that primary care physicians would see patients with such conditions “every day.” However, it is certainly possible that a PCP may run across individuals who are manifesting much less severe “disturbances”, and it may well have been that it was this group, the patients who exhibited mild “mood, thought, or behavioral” symptoms, for whom Zyprexa was being marketed.

Bandick went on to discuss the case of Martha, which was discussed as being a case that seemed to much more strongly resemble dementia than schizophrenia or bipolar disorder. Martha was a hypothetical case that reps were said to have used in order to sell the benefits of Zyprexa to physicians. Bandick said:

Let me take a quick time out and make one quick comment on Martha. What’s the first thing you notice about Martha? She’s old! That does two things. First, it reinforces Zyprexa as a nursing home drug. Our mission is to build a primary care franchise, and let our long-term care team drive the nursing home business. Second, it limits the perception of behavioral disturbances – agitation, tension, anger, hostility all show up in primary care in a variety of packages. When you describe Martha, make her symptoms more prominent than her age.

It is certainly possible that there was a push to get PCP’s to recognize “agitation, tension, anger, [and] hostility” in their patients in a “variety of packages,” which could well mean off-label; the vast majority of people who struggle with these particular issues have neither schizophrenia nor bipolar disorder. At this point, I have not seen enough about the “long-term care team” to offer any intelligent idea as to their strategy, though I would assume that Martha may have been involved.

A few pages later, Bandick stated:

Emphasize patient benefits. And know the difference between a competitor and a “companion.” Drugs like Aricept and Zoloft belong to what we’re calling companion classes, drugs we augment rather than replace.

Aricept (donepezil) is FDA approved in the treatment of Alzheimer’s Disease, and Zoloft is approved in the treatment of depression and some anxiety disorders. Aricept is very rarely used in the treatment of schizophrenia, and Zoloft is not a sensible treatment for symptoms of either schizophrenia or bipolar disorder.

The idea to prescribe Zyprexa along with Aricept seems related to the case of Martha, who, as stated earlier, was a hypothetical patient discussed in sales materials, whose symptoms appear to resemble dementia (for which Aricept is frequently used) as opposed to schizophrenia or bipolar. Bandick’s speech lends credibility to the idea that Zyprexa was to be sold as an add-on for dementia treatment.

Also note that later in the same document, Bandick states that:

We expect approval this summer of an intramuscular formulation which will add two crucial words to our label: agitation and dementia.

It seems Lilly expected Zyprexa would be approved for dementia. Thus, it is possible that they were getting the word out early on Zyprexa for dementia, which would have not been allowable per FDA marketing regulations, although the approval never occurred.

Doctor-to-Doctor Marketing: Outside of sales reps, drug companies frequently use other practicing and/or academic physicians to help market their products. This is known as peer-to-peer marketing. In the current document, Bandick is quoted as saying:

Regarding peer-to-peer, we’ve just completed the second of two speaker training programs and have unleashed more than 130 psychs and PCP’s who are chomping at the bit to help you sell Zyprexa.

Bandick also stated:

We must utilize trained speaker to educate PCPs – not only on Geodon’s [a competitor medication] drawbacks, but especially on Zyprexa’s advantages and benefits to patients.

There is very likely nothing illegal about this practice, but having practicing and/or academic physicians act as salespeople can certainly raise conflicts of interest. While physicians may be more apt to believe other physicians as opposed to a sales rep, the line between sales rep and peer physician blurs significantly when physicians are paid and trained by a sponsoring company such as Lilly.

The document from which all quotes are cited is: Zy100041630.pdf and I thank Furious Seasons for hosting it as well as the other Zyprexa documents. Additional thanks to Alex Berenson of the New York Times, who first discussed Martha in an earlier article.

Stealth Marketing Through Film

Jim Edwards has an interesting story about a stealth marketing campaign by Johnson and Johnson. Here's a couple of snippets:

J and J unit Centocor will next week launch an unadvertised documentary in
movie theaters about patients with Crohn’s disease, rheumatoid arthritis and psoriasis. It is hoped the movie will trigger patients with these conditions to ask their doctors about Remicade, a treatment for inflammatory disorders involving the immune system.

—SNIP—

And the strategy is a significant change for the brand managers at Centocor. In 2005, they placed $13.5 million in consumer advertising behind the brand, according to Nielsen Monitor-Plus. But in 2006, that budget dropped to less than $1 million. Now, without any above-the-line promotion, the company is hoping to attract an audience by encouraging support-group members to attend screenings of the movies, which will be followed by a discussion.

It is also noted that no product is mentioned in the ad, hence my use of the term "stealth marketing."

Pharmalot also weighed in on the matter. Here's a snippet:

"This is a whole new dimension in direct-to-consumer advertising," counters Jerry Avorn, a Harvard researcher and author of "Powerful Medicines: The Benefits, Risks and Costs of Prescription Drugs."What makes me edgy about it is if it is going to be a commercial, you should know it's a commercial. I'm very troubled by the blurring of the lines between advertising and patient education." Okay, we know DTC ads are under attack for flouting side effects and pushing consumers to ask their docs for meds they don't need. So J and J is being clever. Let's give them that. But let's not pretend a 'documentary' isn't an ad when the producer has such a vested interest. What's next? A Broadway musical featuring children with ADHD who sing and dance their way to a happy ending after taking Concerta?

Just an example of some of the good work you'll find at BrandweekNRX and Pharmalot.

Wanna Be a Big Pharma CEO?

Then take the test at Pharma Giles to see if you qualify. It's big fun!

Bipolar in Kids: The BS Train Keeps Running

Earlier in this week, I wondered how Charles Nemeroff, "key opinion leader" in psychiatry at Emory University could make the following statement with a straight face...

"The concerns about antidepressant use in children and adolescents has paradoxically resulted in a reduction in their use, and this has contributed to increased suicide rates."

Note that the data do not actually show a decrease in SSRI prescription for teens during the timeframe when suicides increased, and that even if it did, such a relationship could have just been a coincidence.

But now, I believe that Nemeroff's statement does not even make for the least-supported (i.e., most fictional) statement of the week in psychiatry. The award instead goes to (extended drum roll, please...)

Jean Frazier of Harvard University. The New York Times quoted her as follows:

Dr. Jean Frazier, director of child psychopharmacology at Cambridge Health Alliance and an associate professor at Harvard, said that up to three-quarters of children who exhibit bipolar symptoms become suicidal, and that it is important to treat the problem as early as possible.

"We’re talking about a serious illness with high morbidity, and mortality," Dr. Frazier said, "and for some of these children the medications can be life-giving."

NICE! To my knowledge, there is little to no data to show that bipolar disorder is a valid diagnosis in young children, nor that early treatment is helpful, nor that treatment reduces risk of suicide for "bipolar" children, nor that 75 percent of "bipolar" children become suicidal. This is absolute nonsense, the type of statement that leads to unnecessary medication and leads people to falsely believe that bipolar disorder is a terrible epidemic among youth.

It gets even more detached from reality when we consider the case of Rebecca Riley, a four year old who was prescribed a very high dose of Clonidine, as well as being prescribed Seroquel and Depakote, and who died, reportedly due to the effects of her meds (clonidine seems to be the leading suspect).

Hat tip: Furious Seasons, who has been absolutely on fire as of late.

Zyprexa Story Heating Up

Sure, the New York Times got the ball rolling, but since then it's been Philip Dawdy at Furious Seasons who has been doing the heavy lifting on the Zyprexa documents regarding alleged off-label promotion as well as potential hiding of Zyprexa's side effects.

Earlier this week, he posted an interesting story about a medical writer appearing to have an inordinate amount of input into how research results on Zyprexa were discussed, in which the discussion of Zyprexa's effect on glucose was bandied about by various Lilly personnel. My two cents on this story are available here. The popular blog Junkfood Science also expressed some amazement over this story.

Now, Slate is on board, marking the closest thing to the mainstream media touching this story in weeks. Slate posts a document, made available through Furious Seasons (link to all docs here) in which it seems pretty clear in my mind that Lilly was encouraging Zyprexa to be marketed off label.

Here is a slice of the Slate piece:

The memo sounds an awful lot as though Lilly wants its sales reps to tell primary-care physicians to prescribe Zyprexa for off-label uses. The law permits doctors to do so, but Lilly's executive vice president of science and technology, has stated flatly: "We do not engage in off-label promotion." That's difficult to square with the script on Page 3. "Doctor, you know your patients better than any other clinician," the memo reads, before describing three patient types a primary care physician would commonly see in his office: "Martha," an aged widow who is difficult for her family to manage at home; "David," who suffers from a probable "mood disorder"; and Christine, a twentysomething who struggles with "a history of poor work performance." None of these hypothetical patients would appear to suffer from schizophrenia or bipolar disorder, which are the only two conditions Zyprexa is approved for.

Interesting...

Words of Wisdom

Dr. Roy Poses at Health Care Renewal has a fantastic post about the fabricated data regarding the antibiotic Ketek, as well as the FDA's decision to look the other way regarding Ketek's poor safety record. I strongly suggest y'all read the full post here.

At the bottom of the post, after describing much about the Ketek story, Dr. Poses offers the following:

Unfortunately, these sorts of stories suggest that patients and physicians need to be very skeptical about the integrity of the evidence used to support use of the latest, greatest, and most expensive pharmaceuticals. If the drug industry wants to improve its sagging reputation, it will have to show that it can clean up how it does clinical research. Or perhaps we ought to think about getting drug (and biotechnology and device) companies out of the business of sponsoring clinical research on products in which they have vested interests? Of course, such a change will threaten quite a few peoples' sources of incomes, so we can expect plenty of resistance to it.

Amen!

SSRI's and Suicide: Updated Update

I found more information regarding SSRIs and suicide in youth. I'm going to present two sets of statistics from an article and then illustrate how it is impossible to say that decreasing rates of SSRI prescription led to more suicides, contrary to what many "experts" are saying. From the Seattle Times:

The suicide rate climbed 18 percent from 2003 to 2004 for Americans under age 20, from 1,737 deaths to 1,985. Most suicides occurred in older teens, according to the data — the most current to date from the federal Centers for Disease Control and Prevention.

--SNIP--

Data from Verispan, a prescription tracking firm, show that 3 million antidepressant prescriptions were written for kids through age 12 in 2004, down 6.8 percent from 2003. Among 13- to 19-year-olds, the number dropped less than 1 percent to 8.11 million in 2004.

So, SSRI prescriptions were essentially unchanged in 2004 (less than 1% decrease) among older teens, who are much more likely to commit suicide than youger children. Logically, how could a less than one percent decrease in SSRI prescriptions among older teens lead to a significant increase in suicides? Seriously, folks!

I thank the Seattle Times for at least presenting some data, as other sources (such as ABC News) have just taken it as fact that SSRI prescriptions plummeted without presenting any information.

See a prior post on this topic here, which cites somewhat different data, but essentially comes to the same conclusion that there is no scientific data that link the 2004 increase in suicides to decreasing SSRI prescriptions.

Note: Please see the comments. A couple of readers provided some additional information that was very interesting. Note that my conclusion on this matter remains unchanged.

Zyprexa Ruling

Furious Seasons has a great post on the latest Zyprexa ruling. I won't even attempt to replicate his insightful analysis of the situation.

I will simply focus on one part of the ruling, in which the judge stated:

The harm faced by Lilly is amplified by the fact that the protected documents which respondents seek to disseminate are segments of a large body of information, whose selective and out-of-context disclosure may lead to confusion in the patient community and undeserved reputational harm –– 'what appears damning may, in context after difficult proof, be shown to be neutral or even favorable to the defendant.

Oh, SUCH a bad argument! So unless every single document is released (which Lilly will make sure never happens), then any document released is "out of context." Here's where this line of thinking may lead...

Maybe Lilly can use it to defend themselves regarding Zyprexa and diabetes. "Sure, studies A through Z showed a link between olanzapine and diabetes. But there are other studies which we conducted that put these findings into context. However, we cannot show you said studies because they contain trade secrets. In fact, we insist that all of the earlier published papers linking olanzapine to diabetes be retracted and burned publicly, as they are clearly lacking context."

This trade secrets and out of context thing is blowing my mind. I'm not a lawyer, and I'm glad about that, because I'm not sure I can come to grips with this type of thinking.

This is giving me flashbacks to the British Psychological Society's handling of the Blakemore Brown case and I think I'll need a "safe, gentle psychotropic" to help me handle the stress...

You GO, Graham!

David Graham is once again stepping up to the plate, saying that the FDA needs to get its act together and actually protect the safety of the public. Crazy idea, eh?

According to Reuters:

FDA scientist Dr. David Graham told a congressional hearing the drugmaker and the agency knew "for a long time" about the risk of weight gain from Zyprexa that could trigger diabetes.

"FDA did its typical dragging its feet on post-marketing safety issues," he told Reuters after the U.S. House of Representatives Energy and Commerce subcommittee hearing.

Graham did not review Zyprexa, but said that, after his 2004 public testimony criticizing the FDA's actions on Merck & Co Inc.'s (MRK.N: Quote, Profile, Research) withdrawn Vioxx painkiller, other agency staffers came to him with concerns.

Graham also said that Congress should investigate the FDA's handling of Zyprexa regarding safety concerns. Why are there so few people at the FDA who seem to care about these issues?

Hat Tip: Furious Seasons, PharmaGossip

AstraZeneca: Sued Over Seroquel

Over 10,000 US patients have filed lawsuits against AstraZeneca, alleging that AZ hid dangers of its bestselling atypical antipsychotic quetiapine (Seroquel). The lawsuits allege that AZ was not forthcoming about side effects such as significant weight gain and diabetes. In addition, the lawsuits focus on Seroquel allegedly being promoted for unapproved uses, a point I have suspected (here and here) for a while on this site.

Here's some snippets from the latest story from Bloomberg:

AstraZeneca said in a preliminary annual report filed Feb. 1 that it knew of about 1,200 lawsuits containing the claims of about 8,000 plaintiffs. The company ``has not determined how many additional cases, if any, may have been filed,'' AstraZeneca said in the filing. The company said in May it faced 232 Seroquel suits, including those with multiple claims.

--SNIP--

Seroquel, approved for use for schizophrenia and bipolar disorder, is part of a class of newer antipsychotic drugs including Zyprexa and Johnson & Johnson's Risperdal. Seroquel passed Zyprexa last year as the top-selling atypical antipsychotic, [AZ spokesperson] Minnick said.

AstraZeneca has been sued by 9,956 individuals in U.S. courts over Seroquel, according to a Feb. 5 filing in federal court Orlando, Florida, where the lawsuits have been consolidated in a multidistrict litigation for evidence-gathering and pre- trial hearings.

This includes claims by 7,171 plaintiffs in federal courts, primarily. The claims are made in about 1,500 lawsuits, many of which have multiple plaintiffs.

The suits claim that AstraZeneca knew the risks of Seroquel and didn't warn patients in the U.S. ``until they were finally forced to do so by the FDA,'' according to a complaint filed in federal court in Massachusetts, on behalf of 997 plaintiffs.

--SNIP--

The growth in sales of the drug, from $66 million in 1998 to $2.75 billion in 2005, was spurred by ``AstraZeneca's aggressive marketing of Seroquel,'' according to these patients, whose cases have been transferred to federal court in Orlando.

The marketing ``consisted chiefly of overstating the drug's uses and benefits (including massive off-label promotion), while understating and consciously concealing its life-threatening side effects,'' their complaint said.

Lawyers representing Seroquel users have agreed to limit the claims filed to people who said they developed serious health problems after taking the drug, said attorney Paul Pennock, lead plaintiffs' counsel in the multi-district litigation.

``Everybody involved took a blood oath that we were only going to pursue cases where there was a real injury, like pancreatitis, diabetes or severe exacerbation of existing diabetes,'' said Pennock of Weitz & Luxenberg in New York. ``This was as opposed to the Zyprexa litigation where a lot of people took on all comers,'' he said.

Pennock represents more than 1,700 plaintiffs, about 67 percent of whom were prescribed the medication for off-label uses, including insomnia, depression, anxiety, post-traumatic stress disorder and Alzheimer's, he said.

I'll be keeping my eye on this one. Given that AZ has been studying Seroquel as a treatment for virtutally everything, I strongly expect they "educated" physicians about the results from these studies on conditions other than bipolar and schizophrenia (which have yielded, from what I've seen, not overly impressive results) via doctor dinners, journal article dissemination, continuing medical misinformation, er, education, and the like.

Glucose and Zyprexa

Increased glucose levels are generally considered a risk factor for diabetes. Thus, there has been some concern that olanzapine (Zyprexa) may increase glucose levels, which may relate to the increase in diabetes incidence among users of Zyprexa. Glucose is not the only risk factor for diabetes, but it is generally a concern if a medication tends to increase glucose levels.

The following is some rewording and summarizing of Furious Seasons' recent post on one document related to the Zyprexa-glucose issue:

Lilly had some data indicating that patients who took olanzapine plus mood stabilizers had a mean increase in glucose levels while patients who took placebo plus mood stabilizers showed, on average, a mean decrease in glucose levels.

Dr. Mauricio Tohen of Harvard/Lilly (interesting combination) said that he would like to include the above information when discussing Zyprexa data because he said that the glucose increase was reversible. However, another Lilly official pointed out that since Lilly is aiming for long-term treatment with Zyprexa, pointing out that glucose increases can be reversed when the drug is discontinued does not make much sense. Good point: If the drug has a side effect that can be reversed if you stop taking it, don't tell anyone -- they might not take your drug in the first place!

I'd be interested in tracking down what exactly happened to this data, including whether it ended up hitting the scientific literature in a manner that was accurate, or whether the glucose issue was swept under the carpet. More to come on this one if I can successfully dig up more information.

Mega hat tip to Furious Seasons, who continues his excellent reporting on all things psychiatric, with a special focus on bipolar disorder, schizophrenia, and pharma. I strongly encourage all to read his post on glucose and Zyprexa here.

Medical Writers Moving Up The Ladder

I suppose that the American Medical Writers Association can stand proud and tall. After all, a medical writer seems to have some major pull at Lilly. What am I talking about?

According to documents reviewed by, and available on, Furious Seasons, it seems that the medical writer has a lot of input, perhaps more than the doctors who were running the study, such as Maricio Tohen.

OK, yes, she is a medical writer, so she should write about medical stuff. I'm not denying that. The writer seems to be doing much more than just summarizing study results -- she seems actively involved in spinning the data: "John [Saunders; Regulatory official for Lilly in Europe], here is how I rewrote the HGHL disposition section to try to soften the "only 66 completers language..."

In this study, 53 of 225 olanzapine patients made it to the end of one year on treatment without dropping out. That is a whopping 23.6%. Placebo patients also appeared to have not fared well (only 9.6% completed the year), but the numbers on efficacy and safety and not discussed in much detail in the document outside of some unfavorable data on glucose (more on that later). The point is that the writer is actively attempting to "soften" the language, likely in an attempt to make olanzapine appear more efficacious.

The medical writer is celarly deeply involved with writing whatever this publication turned out to be. I don't know what happened to this publication. Perhaps it was submitted to some refulatory agency? My concern is that this may be reflective of general practice -- the medical writer "softens" language as appropriate and the doctors whose names appear on the study may actually contribute a relatively minimal amount (or none at all) to the final study writeup.

Maybe I'm reading too much into this?

Less SSRI's, MORE Suicide (?)

Some "key opinion leaders" were in the papers again last week stating that the increase in suicide rates for teens was related to a lower prescription rate of SSRIs. Of note, in the news stories I've seen on the topic, no data have actually been provided to show that antidepressant prescription rates went down when the suicide rate increased. The lack of data, naturally, did not prevent the media from running with the story, much in the same way that children sometimes run with scissors.

For examples of reporting on the topic in the media, try MedPage, or ABC for example. The AHRP blog dug up information from the American Psychiatric Association that stated:

In 2003, U.S. physicians wrote 15 million antidepressant prescriptions for patients under age 18, according to FDA data. In the first six months of 2004, antidepressant prescriptions for children increased by almost 8 percent, despite the new drug labeling.

The point here is that antidepressant prescription rates were actually rising when suicide rates were rising, so it is a bit hard to see how FDA warnings were leading to fewer prescriptions which were, in turn, leading to more suicides.

So how does this kind of story gain traction?

Enter Chuck. According to ABC News, Dr. Charles Nemeroff, a "key opinion leader" in psychiatry, (background here and here) said that

"I have no doubt that there is such a relationship," said Dr. Charles Nemeroff, chairman of the department of psychiatry and behavioral sciences at the Emory University School of Medicine.

"The concerns about antidepressant use in children and adolescents has paradoxically resulted in a reduction in their use, and this has contributed to increased suicide rates."

It would appear that Nemeroff has either seen some data nobody else has seen or that he is making things up. Given his cozy relationship with a plethora of drug companies, I'm guessing it's the latter. Even if there were data showing a decrease in SSRI prescriptions as suicide rates increased, surely Nemeroff would know that there could be numerous other factors involved. As is stated in every introductory research class, correlation does not imply causation. Of course, this point appears to be moot, as I've yet to see any evidence that SSRI prescription rates went down as youth suicide rates increased.

It would appear that this latest scare over SSRI deficiency causing suicide is another case of pseudoevidence based medicine.

Hat Tip: AHRP, Hooked.

Update: Nemeroff indeed had some data indicating that SSRI prescriptions have fallen. Yet it now appears that while SSRI usage fell, suicides did not increase. Nemeroff's statement above thus appears incorrect.

British Psychological Society Panned

The British Psychological Society continues to get kicked around the blogosphere. I am, of course, referring to the case of Lisa Blakemore Brown, who dared to take the "wrong" side on a few controversial issues, such as autism and Munchausen's Syndrome. For some background, see here and especially here and here.

The BPS has essentially put Brown on trial to determine if she is fit to practice psychology due to her alleged "paranoia." The funny thing is, when people are really out to get you (as appears to be likely in Brown's case), shouldn't you be afraid? Shouldn't you watch your back?

The BPS refuses to release any transcripts related to Brown's case and also refused to allow an outside witness (whom Brown gave permission to attend) to sit in on the hearings. As stated on the excellent Scientific Misconduct Blog (which has done easily the best reporting on this topic), secrecy is the last refuse of a scoundrel.

The latest: Aubrey Blumsohn has aptly asked why the BPS insists on investigating the Brown case in so much secrecy, yet seems unconcerned with much larger problems. In his latest post, Blumsohn noted that the BPS appears quite uninterested in dealing with issues related to scientific fraud and is likewise uninterested with how a patient group may be influenced by the drug industry.

I can understand that a psychological organization may play hands off regarding medications, as psychologists do not prescribe medications in the vast majority of places. On the other hand, it would seem that issues pertaining to the drug industry are highly relevant to psychologists' clients, as they quite frequently take psychiatric medications. Aren't psychologists supposed to help clients achieve the best possible outcomes? How is it sensible to allocate resources (time and $$$) to the Brown case while ignoring much larger problems? How is the BPS helping the general population by pursuing a dead-end case based on what appears to be shifty evidence at best while ignoring much larger systemic issues such as scientific misconduct and the pernicious influence of the drug industry?

Pseudoevidence Based Medicine

An excellent (per usual) post on Health Care Renewal has some interesting quotes from an article (by Wally Smith) that discusses why all the talk about evidence based medicine is often nothing more than a smokescreen.

I think Wally would agree with the following statement: Physicians often believe that the medicines they prescribe have wonderful evidence of safety and efficacy, yet they frequently fail to consider the many biases in the research process that end up producing "evidence" that often resembles marketing much more than science. Background here and here (among many, many others).

I like the term pseudoevidence based medicine so much that I may have to use it intermittently with such terms as experimercial and evidence b(i)ased medicine.

While I'd like to quote extensively from Wally's piece, I'll send interested readers over to Health Care Renewal to check out the whole thing.

CPP Psychiatrist Wins Award

I'm not sure if this means I can say my site is "award winning," but I can say (with pride?) that one psychiatrist I mentioned on this site recently has been awarded the prestigious Krusty the Klown Award.

The award went to Dr. Siegfried Kasper. In the words of Furious Seasons' Philip Dawdy, who presented (and invented) the award:

[CPP had a post last week about] Siegfried Kasper who likes to affix his name to studies he's never written. Once upon a time, this same clown also stuck his name on a paper David Healy refused to slap his name on for a Phamra [sic] company. And while I know it's fun to bitch about docs doing shady unscientific things and then call the result double-blind, peer-reviewed gold-standard science, I think I need to get into the proper spirit of how medicine really works and give out awards for such behavior. It is in that spirit that I bestow Furious Seasons' first Krusty The Klown Award upon Dr. Siegfried Kasper.

And…

You remember Krusty, right? "I heartily endorse this event or product" was his mantra. I'm sure Kasper knows it by heart.

I only know for sure that Kasper put his name on one paper he did not write, but given that he has purportedly "authored over 800 research reports and reviews," I think it is certainly possible that some of his other work is ghostly. For a little background, see an earlier post here. For more on Krusty-endorsed products, see here.

More on the Krustification of psychiatric "research" coming soon, hopefully.